Cyclacel Pharmaceuticals Inc
- Cyclacel Pharmaceuticals Inc
Cancer Research, Biopharmaceuticals
- Dundee Techno pole, 1 James Lindsay Place Dundee Dundee DD1 5JJ
- 01382 206062
- 01382 206067
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialisation of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.
Products & Services
Through collaborations with leading companies, including Altana, AstraZeneca, Genzyme and GlaxoSmithKline, Cyclacel has built a lengthy pipeline of drug candidates, principally through internal discovery efforts.
Sapacitabine (CYC682), a drug involved in a cell cycle modulation.
Seleciclib (CYC202), a cyclin-dependent kinase (CDK) inhibitor.
CYC116, an Aurora kinase and VEGFR2 inhibitor
Skills & Expertise
The cell cycle lies at the heart of how cancer is caused. Based on recent advances, cell cycle inhibition is generating scientific and commercial interest as an approach to target cancer cells selectively, while generally sparing normally dividing cells.
Extensive experience in research and preclinical, clinical development and commercialisation.
Recognised leaders in the field of cell cycle biology.
A comprehensive pipeline of preclinical and clinical drug candidates as well as products on the market.
Market prominence - the only company currently with an orally available CDK inhibitor in Phase 2 clinical trials.